[New diabetes therapy in clinical trial: will need adapted insulin supply be available soon? (interview by Dr. Judith Neumaier)].
Allolio
Bruno
B
D000818:Animals; D017321:Clinical Trials, Phase I as Topic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000503:physiopathology; D018819:Dipeptidyl Peptidase 4 / Q000187:drug effects* / Q000502:physiology; D005934:Glucagon / Q000097:blood; D052216:Glucagon-Like Peptide 1; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000097:blood; D051379:Mice; D010446:Peptide Fragments / Q000097:blood; D011480:Protease Inhibitors / Q000627:therapeutic use*; D011498:Protein Precursors / Q000097:blood
D007004:Hypoglycemic Agents; D007328:Insulin; D010446:Peptide Fragments; D011480:Protease Inhibitors; D011498:Protein Precursors; D052216:Glucagon-Like Peptide 1; D005934:Glucagon; D018819:Dipeptidyl Peptidase 4